{"id":"covid-19-vaccine","rwe":[],"_fda":{"id":"abd90219-27a3-a0b2-e053-2a95a90a3cbe","set_id":"abd90235-9655-32d0-e053-2a95a90ada4e","openfda":{"unii":["P2OMP71Y62"],"route":["TOPICAL"],"spl_id":["abd90219-27a3-a0b2-e053-2a95a90a3cbe"],"brand_name":["COVID-19 STERILIZING"],"spl_set_id":["abd90235-9655-32d0-e053-2a95a90ada4e"],"package_ndc":["73645-0002-1"],"product_ndc":["73645-0002"],"generic_name":["PHYTONCIDE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["CHAMAECYPARIS OBTUSA WOOD OIL"],"manufacturer_name":["DONGYANG SPECIAL WOOD CORPORATION"],"is_original_packager":[true]},"purpose":["Antibacterial, anti-fungal, indoor air purification, humidity control and insect repellent, sick house syndrome, formaldehyde neutralization, forest bathing effect and stress relief, sterilization deodorization, hand sanitizer, super bacteria inhibition, sleep effect, house mite avoidance, allergy and atopy improvement"],"version":"1","warnings":["Do not drink. Beware of fire. Keep out of reach of children. Avoid direct sunlight. Do not use directly on the skin"],"effective_time":"20200801","active_ingredient":["phytoncide (CHAMAECYPARIS OBTUSA WOOD) OIL"],"inactive_ingredient":["Water"],"indications_and_usage":["Dilute with 5g of oil in 500ml of water"],"dosage_and_administration":["for topical use only"],"spl_product_data_elements":["COVID-19 STERILIZING phytoncide CHAMAECYPARIS OBTUSA WOOD OIL CHAMAECYPARIS OBTUSA WOOD OIL WATER"],"keep_out_of_reach_of_children":["Keep Out of Reach of Children"],"package_label_principal_display_panel":["label"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"Reported 6435 times"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 5291 times"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"Reported 5185 times"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"Reported 4732 times"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"Reported 3991 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 3396 times"},{"date":"","signal":"PAIN IN EXTREMITY","source":"FDA FAERS","actionTaken":"Reported 3284 times"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 2840 times"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 2828 times"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"Reported 2750 times"}],"drugInteractions":[{"drug":"ACE inhibitors","action":"Monitor","effect":"Increased risk of bradycardia"},{"drug":"Angiotensin II receptor blockers","action":"Monitor","effect":"Increased risk of bradycardia"},{"drug":"Antiplatelets","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Anticoagulants","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Aspirin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Blood thinners","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Thalidomide","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Interferons","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Interleukin-2","action":"Avoid","effect":"Decreased antibody response"},{"drug":"TNF-alpha inhibitors","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Vitamin E","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Zidovudine","action":"Avoid","effect":"Decreased antibody response"},{"drug":"Corticosteroids","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Immunosuppressants","action":"Monitor","effect":"Increased risk of infection"},{"drug":"Live vaccines","action":"Avoid","effect":"Increased risk of infection"},{"drug":"Thalidomide","action":"Avoid","effect":"Increased risk of infection"},{"drug":"Interferons","action":"Avoid","effect":"Increased risk of infection"},{"drug":"Interleukin-2","action":"Avoid","effect":"Increased risk of infection"},{"drug":"TNF-alpha inhibitors","action":"Avoid","effect":"Increased risk of infection"},{"drug":"Vitamin E","action":"Avoid","effect":"Increased risk of infection"},{"drug":"Zidovudine","action":"Avoid","effect":"Increased risk of infection"}],"commonSideEffects":[{"effect":"Injection site pain (PAIN)","drugRate":"73.5%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":227,"trialsReporting":1},{"effect":"Fatigue (FATIGUE)","drugRate":"58.3%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":180,"trialsReporting":1},{"effect":"Headache (HEADACHE)","drugRate":"47.6%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":309,"totalAffected":147,"trialsReporting":1},{"effect":"Chills (CHILLS)","drugRate":"37.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":117,"trialsReporting":1},{"effect":"Myalgia (MUSCLE PAIN)","drugRate":"36.9%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":309,"totalAffected":114,"trialsReporting":1},{"effect":"Arthralgia (JOINT PAIN)","drugRate":"24.9%","organSystem":"Musculoskeletal and connective tissue disorders","placeboRate":"","totalAtRisk":309,"totalAffected":77,"trialsReporting":1},{"effect":"Diarrhoea (DIARRHEA)","drugRate":"14.6%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":309,"totalAffected":45,"trialsReporting":1},{"effect":"Injection site erythema (REDNESS)","drugRate":"14.2%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":44,"trialsReporting":1},{"effect":"Pyrexia (FEVER)","drugRate":"13.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":43,"trialsReporting":1},{"effect":"Injection site swelling (SWELLING)","drugRate":"12.9%","organSystem":"General disorders","placeboRate":"","totalAtRisk":309,"totalAffected":40,"trialsReporting":1},{"effect":"Vomiting (VOMITING)","drugRate":"3.9%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":309,"totalAffected":12,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"1.3%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":309,"totalAffected":4,"trialsReporting":1},{"effect":"COVID-19","drugRate":"0.3%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":309,"totalAffected":1,"trialsReporting":1}],"contraindications":["History of a severe allergic reaction* (e.g., anaphylaxis†) after a previous dose or to a component of the COVID-19 vaccine‡","History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine"],"specialPopulations":{"Pregnancy":"COVID-19 vaccination offers the greatest benefit if you are at higher risk for severe illness, including if you are pregnant. Pregnancy increases your risk of becoming very sick from COVID-19. COVID-19 vaccination during pregnancy has not been linked to increased health risks for pregnant women or babies. It helps reduce the risk for severe illness from COVID-19. COVID-19 vaccines are not associated with fertility problems in women or men.","Geriatric use":"text","Paediatric use":"The 2025-2026 COVID-19 vaccine recommendations were updated for people ages 6 months and older.","Renal impairment":"text","Hepatic impairment":"text"},"seriousAdverseEvents":[{"event":"Meningitis bacterial","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Seizure","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.3%"},{"event":"Thrombocytopenia","detail":"Blood and lymphatic system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Acute cardiac event","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Acute myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Atrial fibrillation","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Bradycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac arrest","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac failure acute","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiac failure congestive","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cardiogenic shock","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Coronary artery stenosis","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Myocardial infarction","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Sinus bradycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Ventricular tachycardia","detail":"Cardiac disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Vertigo positional","detail":"Ear and labyrinth disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Non-cardiac chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Abdominal pain","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Constipation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Duodenal ulcer perforation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Impaired gastric emptying","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Intestinal obstruction","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pancreatitis","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Umbilical hernia, obstructive","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Biliary colic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cholecystitis acute","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hepatic steatosis","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hepatitis alcoholic","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypertransaminasaemia","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":["Pfizer vaccine, Moderna vaccine, Johnson & Johnson vaccine","SARS-CoV-2 vaccine","Pfizer-BioNTech COVID-19 vaccine","Moderna COVID-19 vaccine","COVID-19 Vaccine Moderna Intramuscular Injection"],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=COVID-19 Vaccine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:37.747976+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:43.124224+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:37.822513+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COVID-19 Vaccine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:43.447360+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:40:36.484944+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:40:36.484962+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068383/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:44.893083+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T08:32:22.416754+00:00"}},"allNames":"covid-19 sterilizing","offLabel":[],"timeline":[],"_dailymed":{"setId":"48c86164-de07-4041-b9dc-f2b5744714e5","title":"COMIRNATY (COVID-19 VACCINE, MRNA) INJECTION, SUSPENSION [PFIZER LABORATORIES DIV PFIZER INC]","labeler":""},"aiSummary":"The COVID-19 Vaccine, developed by Pfizer, is a marketed drug for the prevention of COVID-19 in individuals 6 months of age and older. It has undergone 100 trials and has been the subject of 18,671 publications. The vaccine has generated $5.353 billion in revenue. The mechanism of action is not specified. The COVID-19 Vaccine has key indications for prevention of COVID-19 in various age groups. It has clinical differentiation from other COVID-19 vaccines. The commercial significance of the COVID-19 Vaccine is substantial, with high revenue and widespread use. Pipeline developments for the COVID-19 Vaccine are not specified.","brandName":"Covid-19 Sterilizing","ecosystem":[],"isGeneric":true,"mechanism":{"target":"SARS-CoV-2","novelty":"best-in-class","modality":"viral vector|protein subunit","drugClass":"vaccine","explanation":"","oneSentence":"","technicalDetail":"The COVID-19 Vaccine uses a viral vector or protein subunit to stimulate an immune response against SARS-CoV-2. This results in the production of antibodies that can neutralize the virus. The vaccine is administered via injection and is typically given in two doses."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"-52%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$5.353B","peakSalesEstimate":"$5.353B"},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=COVID-19 Vaccine","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=COVID-19%20Vaccine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=COVID-19 Vaccine","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":6,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":7,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:32:23.707930+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Paxlovid","company":"Pfizer","advantage":"Antiviral treatment for COVID-19"},{"name":"Remdesivir","company":"Gilead Sciences","advantage":"Antiviral treatment for COVID-19"},{"name":"Molnupiravir","company":"Merck & Co.","advantage":"Antiviral treatment for COVID-19"},{"name":"Lagevrio","company":"Merck & Co.","advantage":"Antiviral treatment for COVID-19"},{"name":"Actemra","company":"Roche","advantage":"Treatment for severe COVID-19"},{"name":"Nuvaxovid","company":"Novavax","advantage":"Alternative COVID-19 vaccine"},{"name":"Veklury","company":"Gilead Sciences","advantage":"Alternative COVID-19 treatment"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"covid-19 vaccine","indications":{"approved":[{"name":"Prevention of COVID-19 in individuals 6 months of age and older","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 5 years of age and older for the Pfizer-BioNTech COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older for the Moderna COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 6 months of age and older for the Novavax COVID-19 Vaccine","regulator":"FDA"},{"name":"Prevention of COVID-19 in individuals 12 years of age and older for the Janssen COVID-19 Vaccine","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT07183709","phase":"PHASE1","title":"Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-02-02","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05392075","phase":"","title":"COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-03-15","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":100},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT05765773","phase":"PHASE2","title":"An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-01","conditions":"Corona Virus Infection, Vaccine, COVID-19","enrollment":200},{"nctId":"NCT04579588","phase":"","title":"Understanding Immunity to the Flu Vaccine in COVID-19 Patients","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Corona Virus Infection, Flu Vaccine, Immunity","enrollment":230},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT06181292","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-11-15","conditions":"SARS-CoV2 Infection","enrollment":913},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT07096245","phase":"NA","title":"Conectados: Social Networks and Social Media for Vaccine Uptake","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2025-09-10","conditions":"Vaccination","enrollment":507},{"nctId":"NCT05672355","phase":"PHASE2","title":"A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"Chronic Lymphocytic Leukemia, COVID-19 Infection","enrollment":80},{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT06650462","phase":"NA","title":"Evaluating a Community-Led COVID-19 Testing Intervention to Address Mistrust - Study 1","status":"COMPLETED","sponsor":"Old Dominion University","startDate":"2024-07-02","conditions":"COVID-19, Trust","enrollment":57},{"nctId":"NCT07166770","phase":"NA","title":"Community-Led COVID-19 Testing Intervention to Address Mistrust","status":"COMPLETED","sponsor":"Old Dominion University","startDate":"2025-07-01","conditions":"COVID-19, Trust","enrollment":49},{"nctId":"NCT04992195","phase":"","title":"Impact of COVID-19 Vaccines on Cerebrovascular Health","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2021-07-05","conditions":"Stroke, Stroke, Acute, Stroke, Ischemic","enrollment":500},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT06141850","phase":"NA","title":"Promoting Engagement and COVID-19 Testing for Health","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-12-06","conditions":"COVID-19","enrollment":290},{"nctId":"NCT07416539","phase":"PHASE1","title":"Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19","status":"RECRUITING","sponsor":"Rokote Laboratories Finland Oy","startDate":"2026-02-10","conditions":"COVID - 19, SARS CoV-2","enrollment":20},{"nctId":"NCT06505993","phase":"NA","title":"Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia","status":"SUSPENDED","sponsor":"Marc Kiviniemi","startDate":"2026-09","conditions":"COVID-19, Vaccine Hesitancy","enrollment":2250},{"nctId":"NCT04839146","phase":"PHASE1","title":"Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-03-11","conditions":"Covid19, Severe Acute Respiratory Syndrome, SARS-CoV-2 Infection","enrollment":45},{"nctId":"NCT07079670","phase":"PHASE3","title":"Safety and Immunogenicity of NVX-CoV2705","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":676},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT04977024","phase":"PHASE2","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GeoVax, Inc.","startDate":"2021-09-27","conditions":"COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia","enrollment":63},{"nctId":"NCT07222384","phase":"PHASE3","title":"A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":343},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT07400848","phase":"","title":"Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome","status":"RECRUITING","sponsor":"University of Bern","startDate":"2026-02-15","conditions":"Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue","enrollment":200},{"nctId":"NCT04639466","phase":"PHASE1, PHASE2","title":"A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"GeoVax, Inc.","startDate":"2020-11-19","conditions":"COVID-19 Infection","enrollment":119},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT07095231","phase":"PHASE1","title":"Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-11","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06065176","phase":"PHASE4","title":"The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection","status":"COMPLETED","sponsor":"Sarang K. Yoon, DO, MOH","startDate":"2023-11-22","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":1188},{"nctId":"NCT05046002","phase":"","title":"COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2021-08-11","conditions":"Myocarditis, Pericarditis","enrollment":400},{"nctId":"NCT06381739","phase":"PHASE2","title":"A Trial of a Next Generation COVID-19 Vaccine Delivered by Inhaled Aerosol","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-03-25","conditions":"COVID-19 Infection","enrollment":350},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT06036134","phase":"NA","title":"Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents","status":"COMPLETED","sponsor":"Arizona State University","startDate":"2023-12-01","conditions":"Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior","enrollment":80},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT05078905","phase":"","title":"Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-10-13","conditions":"COVID-19, Vaccination, Healthy Volunteer","enrollment":1200},{"nctId":"NCT06547814","phase":"NA","title":"COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2024-08-05","conditions":"COVID-19","enrollment":20},{"nctId":"NCT06108076","phase":"EARLY_PHASE1","title":"Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-01-16","conditions":"Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction","enrollment":10},{"nctId":"NCT04869592","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-04-25","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT05408312","phase":"PHASE1","title":"Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2022-06-18","conditions":"COVID-19 Pneumonia","enrollment":234},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT05160636","phase":"","title":"A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-01-31","conditions":"COVID-19, Coronavirus Disease 2019, Influenza","enrollment":999},{"nctId":"NCT05766189","phase":"NA","title":"Wastewater Surveillance to Boost COVID-19 Vaccine Uptake","status":"COMPLETED","sponsor":"Syracuse University","startDate":"2023-03-01","conditions":"Vaccination, Wastewater Surveillance","enrollment":100000},{"nctId":"NCT05926544","phase":"NA","title":"COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-10-04","conditions":"COVID-19","enrollment":16},{"nctId":"NCT05541861","phase":"PHASE1","title":"Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2022-11-08","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":383},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT04872738","phase":"","title":"Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-05-07","conditions":"Breast Cancer Related Lymphedema, Covid19","enrollment":714},{"nctId":"NCT04959734","phase":"","title":"COVID-19 Impact on RSV Emergency Presentations","status":"RECRUITING","sponsor":"University Hospitals, Leicester","startDate":"2021-06-25","conditions":"Bronchiolitis; Respiratory Syncytial Virus","enrollment":3000},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT05172011","phase":"","title":"Understanding the Long-term Impact of COVID on Children and Families","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-03-01","conditions":"SARS-CoV-2 Infection","enrollment":15028},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT04750720","phase":"NA","title":"Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2020-08-27","conditions":"Covid19, SARS-CoV-2","enrollment":187},{"nctId":"NCT06374394","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":841},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT05919472","phase":"NA","title":"Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women","status":"COMPLETED","sponsor":"Nicole Stoffel","startDate":"2023-07-01","conditions":"Iron Deficiency Anemia","enrollment":180},{"nctId":"NCT07300839","phase":"PHASE3","title":"A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-10","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":25500},{"nctId":"NCT04952766","phase":"PHASE4","title":"Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults","status":"COMPLETED","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2021-03-26","conditions":"Kidney Transplant, Myeloma, Cancer","enrollment":196},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT07069309","phase":"PHASE3","title":"A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-08","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":760},{"nctId":"NCT05228275","phase":"","title":"Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-04-08","conditions":"COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm","enrollment":549},{"nctId":"NCT04852289","phase":"","title":"A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute on Aging (NIA)","startDate":"2021-04-20","conditions":"COVID-19","enrollment":78},{"nctId":"NCT05096091","phase":"","title":"International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-16","conditions":"COVID-19","enrollment":5399},{"nctId":"NCT06821126","phase":"PHASE1, PHASE2","title":"Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-05-09","conditions":"Healthy","enrollment":238},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT05234372","phase":"NA","title":"MiVacunaLA: an Intervention to Improve COVID-19 Vaccination Behaviors Among Latinos","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2022-06-01","conditions":"COVID-19 Pandemic","enrollment":468},{"nctId":"NCT06469788","phase":"NA","title":"Testimonials and Navigation in Rheumatology","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2024-12-18","conditions":"Rheumatologic Disease, Autoimmune Diseases","enrollment":1170},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT04939519","phase":"NA","title":"SCALE-UP Utah: Community-Academic Partnership to Address COVID-19 Vaccination Rates Among Utah Community Health Centers","status":"COMPLETED","sponsor":"University of Utah","startDate":"2021-03-29","conditions":"Covid19","enrollment":65300},{"nctId":"NCT06851611","phase":"PHASE1","title":"The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus","status":"COMPLETED","sponsor":"Rokote Laboratories Finland Oy","startDate":"2025-01-21","conditions":"COVID19, Sars-Cov-2","enrollment":40},{"nctId":"NCT05655351","phase":"EARLY_PHASE1","title":"Effect of a Vaccination Against COVID-19 on Monocyte Production of Oxygenated Derivatives.","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-12-21","conditions":"CORONAVIRUS INFECTIONS","enrollment":30},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT06178991","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-12-20","conditions":"Influenza, COVID-19","enrollment":8795},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT04659759","phase":"","title":"COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-11-17","conditions":"Covid19","enrollment":105},{"nctId":"NCT05543993","phase":"","title":"COVID Booster in Pregnancy and Lactation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-09-29","conditions":"COVID-19","enrollment":150},{"nctId":"NCT06731127","phase":"","title":"Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People With HIV","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2021-04-10","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT05212948","phase":"PHASE3","title":"A Study of S-268019 for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Shionogi","startDate":"2021-12-25","conditions":"SARS-CoV-2","enrollment":9902},{"nctId":"NCT07254442","phase":"","title":"Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing","status":"COMPLETED","sponsor":"Zonguldak Bulent Ecevit University","startDate":"2021-12-01","conditions":"Hearing, COVID - 19, Ototoxicity","enrollment":90},{"nctId":"NCT04830046","phase":"","title":"Covid-19 Vaccine Responsiveness in MM and Waldenstrom","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-04-15","conditions":"Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder","enrollment":146},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05164016","phase":"","title":"Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-06-29","conditions":"Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer","enrollment":21},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237},{"nctId":"NCT05436834","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-21","conditions":"SARS-CoV-2","enrollment":1807},{"nctId":"NCT06923137","phase":"","title":"A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection","enrollment":1},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000}],"_emaApprovals":[{"date":"","name":"COVID-19 Vaccine","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://finance.yahoo.com/news/pfizer-sales-fall-continued-lower-122100353.html","date":"2026-04-07","type":"news","title":"Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand","source":"finance.yahoo.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides","date":"2026-04-07","type":"news","title":"Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full ...","source":"www.pfizer.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-authorization","date":"2026-04-07","type":"news","title":"Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for ...","source":"www.pfizer.com"},{"url":"https://apic.org/public-policy-updates/fda-approves-manufacturing-change-for-pfizer-covid-19-vaccine/","date":"2026-04-07","type":"news","title":"FDA Approves Manufacturing Change for Pfizer COVID-19 Vaccine","source":"apic.org"}],"manufacturing":[{"role":"Manufacturer","site":"DONGYANG SPECIAL WOOD CORPORATION","location":"","operator":"DONGYANG SPECIAL WOOD CORPORATION"}],"molecularData":{"oral":false,"chemblId":"CHEMBL6068383","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Topical"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL6068383","pubchemSID":"497620527"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"DONGYANG SPECIAL WOOD CORPORATION","relationship":"Originator"}],"publicationCount":18731,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 09:33:29.722758+00","biosimilarFilings":[],"commercialAnalysis":{"text":"Pfizer's COVID-19 Sterilizing (COVID-19 Vaccine) has experienced a decline in revenue, with full-year 2025 revenues of $62.6 billion reflecting a 2% year-over-year operational decline [1]. Excluding contributions from Paxlovid and Comirnaty, revenues grew 6% operationally [2]. The COVID-19 vaccine's revenue is expected to be approximately $1.5 billion lower in 2026 compared to 2025, with an additional $1.5 billion negative revenue impact due to loss of exclusivity (LOE) products [3].\n\nThe competitive landscape for COVID-19 vaccines is intense, with multiple players vying for market share. Pfizer's COVID-19 vaccine faces threats from competitors such as Moderna and Novavax, which have their own COVID-19 vaccines [4]. Additionally, the patent cliff for COVID-19 vaccines is approaching, which may lead to increased competition and decreased revenue for Pfizer.\n\nKey upcoming catalysts for Pfizer's COVID-19 vaccine include the potential for label expansions and the entry of new competitors into the market. Pfizer has a late-stage pipeline with 11 key pivotal study starts in 2025 and approximately 20 key pivotal study starts planned for 2026 [5]. However, the impact of these catalysts on revenue is uncertain and may be influenced by various factors, including regulatory approvals and market demand.\n\nIn terms of market outlook, Pfizer's COVID-19 vaccine is expected to continue to face challenges in the market. The company's full-year 2026 revenue guidance is $59.5 to $62.5 billion, with operational revenue growth at the midpoint excluding COVID-19 and LOE products expected to be approximately 4% year-over-year [6].","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://finance.yahoo.com/news/pfizer-sales-fall-continued-lower-122100353.html","date":"","title":"Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand","source":"finance.yahoo.com"},{"url":"https://s206.q4cdn.com/795948973/files/doc_financials/2025/q4/Q4-2025-PFE-Earnings-Release-FINAL2.pdf","date":"","title":"[PDF] Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 ...","source":"s206.q4cdn.com"},{"url":"https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides","date":"","title":"Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full ...","source":"www.pfizer.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar 28","pmid":"41903103","title":"Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Thailand: Epidemiological Data Update.","journal":"Pulmonary therapy"},{"date":"2026 Mar 28","pmid":"41902725","title":"Beyond aggregate estimates: stratified self-controlled case series analyses and insights into COVID-19 vaccine safety.","journal":"Expert review of vaccines"},{"date":"2026 Mar 14","pmid":"41901323","title":"Incidence of Guillain-Barré Syndrome Following COVID-19 Vaccination and SARS-CoV-2 Infection: A Population-Based Cohort Study Using the Valencia Health System Integrated Database (Spain).","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 6","pmid":"41899704","title":"Using the Diffusion of Innovation Theory to Understand COVID-19 Booster Hesitancy in Adults.","journal":"International journal of environmental research and public health"},{"date":"2026 Mar 26","pmid":"41895292","title":"p16(High)-expressing immune cells control disease tolerance as a defense and health span-extending strategy.","journal":"Immunity"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"1.38","nctId":"NCT06178991","phase":"PHASE3","pValue":"","ciLower":"1.25","ciUpper":"1.52","endpoint":"Cohort 2: Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Strain-Specific Hemagglutination Inhibition Assay (HAI) Titers at 4 Weeks After Vaccination: Non-inferiority","enrollment":8795}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":22,"withResults":2},"validation":{"fieldsValidated":4,"lastValidatedAt":"2026-04-20T08:32:23.707930+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}